Skip to main content
Top
Published in: Inflammation 4/2021

01-08-2021 | Septicemia | Original Article

MicroRNA-181b Inhibits Inflammatory Response and Reduces Myocardial Injury in Sepsis by Downregulating HMGB1

Authors: Lan Ling, Lida Zhi, Haifeng Wang, Yihuan Deng, Chengdong Gu

Published in: Inflammation | Issue 4/2021

Login to get access

Abstract

MicroRNAs (miRNAs) are short endogenous noncoding RNAs regulating protein translation. However, the specific mechanism by which miR-181b influences sepsis via high-mobility group box-1 protein (HMGB1) still remains unknown. Thus, the aim of this study is to investigate the mechanism of miR-181b in regulating inflammatory response in sepsis-induced myocardial injury through targeting high-mobility group box-1 protein (HMGB1). Through cecal ligation and puncture (CLP), the rat model of sepsis was established. Then, the effect of altered expression of miR-181b and HMGB1 on cardiomyocytes was investigated. The positive expression rate of HMGB1, concentration of inflammatory factors, and serum myocardial enzyme of myocardial tissues were determined. Besides, the binding site between miR-181b and HMGB1 was determined by bioinformatics information and dual-luciferase reporter gene assay. The expression of related genes in cells of each group was determined by RT-qPCR and western blot analysis, and the apoptosis rate of transfected cells in each group was determined by TUNEL assay. HMGB1 expression and inflammatory factors were significantly increased in myocardial tissue of rats with sepsis. Cell morphology and the infiltration of inflammatory cells were significantly improved by overexpression of miR-181b. miR-181b directly targeted HMGB1, and downregulation of HMGB1 reduced inflammatory factors and myocardial injury and inhibited cardiomyocyte apoptosis in sepsis. This present study suggests that miR-181b decreased inflammatory factors and reduced myocardial injury in sepsis through downregulation of HMGB1. Thus, a better understanding of this process may aid in the development of novel therapeutic agents in sepsis.
Literature
1.
go back to reference Rhodes, A., L.E. Evans, W. Alhazzani, M.M. Levy, M. Antonelli, R. Ferrer, et al. 2017. Surviving Sepsis Campaign: international guidelines for management of sepsis and septic shock: 2016. Crit Care Med 45 (3): 486–552.CrossRef Rhodes, A., L.E. Evans, W. Alhazzani, M.M. Levy, M. Antonelli, R. Ferrer, et al. 2017. Surviving Sepsis Campaign: international guidelines for management of sepsis and septic shock: 2016. Crit Care Med 45 (3): 486–552.CrossRef
2.
go back to reference Delano, M.J., and P.A. Ward. 2016. Sepsis-induced immune dysfunction: can immune therapies reduce mortality? J Clin Invest 126 (1): 23–31.CrossRef Delano, M.J., and P.A. Ward. 2016. Sepsis-induced immune dysfunction: can immune therapies reduce mortality? J Clin Invest 126 (1): 23–31.CrossRef
3.
go back to reference Lu, Z.Q., J.X. Lu, and Y.J. Deng. 2015. Glucocorticoids offer protection against myocardial injury in a murine model of sepsis. Int J Clin Exp Med 8 (8): 12211–12218.PubMedPubMedCentral Lu, Z.Q., J.X. Lu, and Y.J. Deng. 2015. Glucocorticoids offer protection against myocardial injury in a murine model of sepsis. Int J Clin Exp Med 8 (8): 12211–12218.PubMedPubMedCentral
4.
go back to reference Zhang, X., S. Dong, Y. Qin, and X. Bian. 2015. Protective effect of erythropoietin against myocardial injury in rats with sepsis and its underlying mechanisms. Mol Med Rep 11 (5): 3317–3329.CrossRef Zhang, X., S. Dong, Y. Qin, and X. Bian. 2015. Protective effect of erythropoietin against myocardial injury in rats with sepsis and its underlying mechanisms. Mol Med Rep 11 (5): 3317–3329.CrossRef
5.
go back to reference Zhang, M., X. Wang, B. Bai, R. Zhang, Y. Li, and Y. Wang. 2016. Oxymatrine protects against sepsis-induced myocardial injury via inhibition of the TNF-alpha/p38-MAPK/caspase-3 signaling pathway. Mol Med Rep 14 (1): 551–559.CrossRef Zhang, M., X. Wang, B. Bai, R. Zhang, Y. Li, and Y. Wang. 2016. Oxymatrine protects against sepsis-induced myocardial injury via inhibition of the TNF-alpha/p38-MAPK/caspase-3 signaling pathway. Mol Med Rep 14 (1): 551–559.CrossRef
6.
go back to reference Sun, X., B. Icli, A.K. Wara, N. Belkin, S. He, L. Kobzik, et al. 2012. MicroRNA-181b regulates NF-kappaB-mediated vascular inflammation. J Clin Invest 122 (6): 1973–1990.PubMedPubMedCentral Sun, X., B. Icli, A.K. Wara, N. Belkin, S. He, L. Kobzik, et al. 2012. MicroRNA-181b regulates NF-kappaB-mediated vascular inflammation. J Clin Invest 122 (6): 1973–1990.PubMedPubMedCentral
7.
go back to reference O’Connell, R.M., D.S. Rao, A.A. Chaudhuri, and D. Baltimore. 2010. Physiological and pathological roles for microRNAs in the immune system. Nat Rev Immunol 10 (2): 111–122.CrossRef O’Connell, R.M., D.S. Rao, A.A. Chaudhuri, and D. Baltimore. 2010. Physiological and pathological roles for microRNAs in the immune system. Nat Rev Immunol 10 (2): 111–122.CrossRef
8.
go back to reference Peng, Z., J. Li, Y. Li, X. Yang, S. Feng, S. Han, et al. 2013. Downregulation of miR-181b in mouse brain following ischemic stroke induces neuroprotection against ischemic injury through targeting heat shock protein A5 and ubiquitin carboxyl-terminal hydrolase isozyme L1. J Neurosci Res 91 (10): 1349–1362.CrossRef Peng, Z., J. Li, Y. Li, X. Yang, S. Feng, S. Han, et al. 2013. Downregulation of miR-181b in mouse brain following ischemic stroke induces neuroprotection against ischemic injury through targeting heat shock protein A5 and ubiquitin carboxyl-terminal hydrolase isozyme L1. J Neurosci Res 91 (10): 1349–1362.CrossRef
9.
go back to reference McClure, C., M.B. McPeak, D. Youssef, Z.Q. Yao, C.E. McCall, and M. El Gazzar. 2017. Stat3 and C/EBPbeta synergize to induce miR-21 and miR-181b expression during sepsis. Immunol Cell Biol 95 (1): 42–55.CrossRef McClure, C., M.B. McPeak, D. Youssef, Z.Q. Yao, C.E. McCall, and M. El Gazzar. 2017. Stat3 and C/EBPbeta synergize to induce miR-21 and miR-181b expression during sepsis. Immunol Cell Biol 95 (1): 42–55.CrossRef
10.
go back to reference Hutchison, E.R., E.M. Kawamoto, D.D. Taub, A. Lal, K. Abdelmohsen, Y. Zhang, et al. 2013. Evidence for miR-181 involvement in neuroinflammatory responses of astrocytes. Glia 61 (7): 1018–1028.CrossRef Hutchison, E.R., E.M. Kawamoto, D.D. Taub, A. Lal, K. Abdelmohsen, Y. Zhang, et al. 2013. Evidence for miR-181 involvement in neuroinflammatory responses of astrocytes. Glia 61 (7): 1018–1028.CrossRef
11.
go back to reference Lu, F., J. Zhang, M. Ji, P. Li, Y. Du, H. Wang, et al. 2014. miR-181b increases drug sensitivity in acute myeloid leukemia via targeting HMGB1 and Mcl-1. Int J Oncol 45 (1): 383–392.CrossRef Lu, F., J. Zhang, M. Ji, P. Li, Y. Du, H. Wang, et al. 2014. miR-181b increases drug sensitivity in acute myeloid leukemia via targeting HMGB1 and Mcl-1. Int J Oncol 45 (1): 383–392.CrossRef
12.
go back to reference Liu, Y., X. Hu, D. Xia, and S. Zhang. 2016. MicroRNA-181b is downregulated in non-small cell lung cancer and inhibits cell motility by directly targeting HMGB1. Oncol Lett 12 (5): 4181–4186.CrossRef Liu, Y., X. Hu, D. Xia, and S. Zhang. 2016. MicroRNA-181b is downregulated in non-small cell lung cancer and inhibits cell motility by directly targeting HMGB1. Oncol Lett 12 (5): 4181–4186.CrossRef
13.
go back to reference Gentile, L.F., and L.L. Moldawer. 2014. HMGB1 as a therapeutic target for sepsis: it’s all in the timing! Expert Opin Ther Targets 18 (3): 243–245.CrossRef Gentile, L.F., and L.L. Moldawer. 2014. HMGB1 as a therapeutic target for sepsis: it’s all in the timing! Expert Opin Ther Targets 18 (3): 243–245.CrossRef
14.
go back to reference Yang, H., H. Wang, S.S. Chavan, and U. Andersson. 2015. High mobility group box protein 1 (HMGB1): the prototypical endogenous danger molecule. Mol Med 21 (Suppl 1): S6–S12.CrossRef Yang, H., H. Wang, S.S. Chavan, and U. Andersson. 2015. High mobility group box protein 1 (HMGB1): the prototypical endogenous danger molecule. Mol Med 21 (Suppl 1): S6–S12.CrossRef
15.
go back to reference Hubbard, W.J., M. Choudhry, M.G. Schwacha, J.D. Kerby, L.W. Rue, K.I. Bland 3rd, et al. 2005. Cecal ligation and puncture. Shock 24 (Suppl 1): 52–57.CrossRef Hubbard, W.J., M. Choudhry, M.G. Schwacha, J.D. Kerby, L.W. Rue, K.I. Bland 3rd, et al. 2005. Cecal ligation and puncture. Shock 24 (Suppl 1): 52–57.CrossRef
16.
go back to reference Kong, W., K. Kang, Y. Gao, H. Liu, X. Meng, Y. Cao, et al. 2018. GTS-21 protected against LPS-induced sepsis myocardial injury in mice through alpha7nAChR. Inflammation 41 (3): 1073–1083.CrossRef Kong, W., K. Kang, Y. Gao, H. Liu, X. Meng, Y. Cao, et al. 2018. GTS-21 protected against LPS-induced sepsis myocardial injury in mice through alpha7nAChR. Inflammation 41 (3): 1073–1083.CrossRef
17.
go back to reference Wang, H., M.F. Ward, and A.E. Sama. 2009. Novel HMGB1-inhibiting therapeutic agents for experimental sepsis. Shock 32 (4): 348–357.CrossRef Wang, H., M.F. Ward, and A.E. Sama. 2009. Novel HMGB1-inhibiting therapeutic agents for experimental sepsis. Shock 32 (4): 348–357.CrossRef
18.
go back to reference Wang, H., M.F. Ward, and A.E. Sama. 2014. Targeting HMGB1 in the treatment of sepsis. Expert Opin Ther Targets 18 (3): 257–268.CrossRef Wang, H., M.F. Ward, and A.E. Sama. 2014. Targeting HMGB1 in the treatment of sepsis. Expert Opin Ther Targets 18 (3): 257–268.CrossRef
19.
go back to reference Huang, W., Y. Tang, and L. Li. 2010. HMGB1, a potent proinflammatory cytokine in sepsis. Cytokine 51 (2): 119–126.CrossRef Huang, W., Y. Tang, and L. Li. 2010. HMGB1, a potent proinflammatory cytokine in sepsis. Cytokine 51 (2): 119–126.CrossRef
20.
go back to reference Gao, Z., L. Wang, J. Wang, F. Yang, and J. Qu. 2017. Molecular mechanism of miR-181b in heart disease due to pregnancy-induced hypertension syndrome. Exp Ther Med 14 (4): 2953–2959.CrossRef Gao, Z., L. Wang, J. Wang, F. Yang, and J. Qu. 2017. Molecular mechanism of miR-181b in heart disease due to pregnancy-induced hypertension syndrome. Exp Ther Med 14 (4): 2953–2959.CrossRef
21.
go back to reference Li, D., W. Jian, C. Wei, H. Song, Y. Gu, Y. Luo, et al. 2014. Down-regulation of miR-181b promotes apoptosis by targeting CYLD in thyroid papillary cancer. Int J Clin Exp Pathol 7 (11): 7672–7680.PubMedPubMedCentral Li, D., W. Jian, C. Wei, H. Song, Y. Gu, Y. Luo, et al. 2014. Down-regulation of miR-181b promotes apoptosis by targeting CYLD in thyroid papillary cancer. Int J Clin Exp Pathol 7 (11): 7672–7680.PubMedPubMedCentral
22.
go back to reference Yang, L., Y.L. Wang, S. Liu, P.P. Zhang, Z. Chen, M. Liu, et al. 2014. miR-181b promotes cell proliferation and reduces apoptosis by repressing the expression of adenylyl cyclase 9 (AC9) in cervical cancer cells. FEBS Lett 588 (1): 124–130.CrossRef Yang, L., Y.L. Wang, S. Liu, P.P. Zhang, Z. Chen, M. Liu, et al. 2014. miR-181b promotes cell proliferation and reduces apoptosis by repressing the expression of adenylyl cyclase 9 (AC9) in cervical cancer cells. FEBS Lett 588 (1): 124–130.CrossRef
23.
go back to reference Faridvand, Y., S. Nozari, V. Vahedian, N. Safaie, M. Pezeshkian, P. Haddadi, et al. 2019. Nrf2 activation and down-regulation of HMGB1 and MyD88 expression by amnion membrane extracts in response to the hypoxia-induced injury in cardiac H9c2 cells. Biomed Pharmacother 109: 360–368.CrossRef Faridvand, Y., S. Nozari, V. Vahedian, N. Safaie, M. Pezeshkian, P. Haddadi, et al. 2019. Nrf2 activation and down-regulation of HMGB1 and MyD88 expression by amnion membrane extracts in response to the hypoxia-induced injury in cardiac H9c2 cells. Biomed Pharmacother 109: 360–368.CrossRef
24.
go back to reference Li, Q., Z.M. Li, S.Y. Sun, L.P. Wang, P.X. Wang, Z. Guo, et al. 2018. PARP1 interacts with HMGB1 and promotes its nuclear export in pathological myocardial hypertrophy. Acta Pharmacol Sin. Li, Q., Z.M. Li, S.Y. Sun, L.P. Wang, P.X. Wang, Z. Guo, et al. 2018. PARP1 interacts with HMGB1 and promotes its nuclear export in pathological myocardial hypertrophy. Acta Pharmacol Sin.
25.
go back to reference Zhou, Y., Y. Li, and T. Mu. 2015. HMGB1 neutralizing antibody attenuates cardiac injury and apoptosis induced by hemorrhagic shock/resuscitation in rats. Biol Pharm Bull 38 (8): 1150–1160.CrossRef Zhou, Y., Y. Li, and T. Mu. 2015. HMGB1 neutralizing antibody attenuates cardiac injury and apoptosis induced by hemorrhagic shock/resuscitation in rats. Biol Pharm Bull 38 (8): 1150–1160.CrossRef
26.
go back to reference Luo, P., Y. Zhu, M. Chen, H. Yan, B. Yang, X. Yang, et al. 2018. HMGB1 contributes to adriamycin-induced cardiotoxicity via up-regulating autophagy. Toxicol Lett 292: 115–122.CrossRef Luo, P., Y. Zhu, M. Chen, H. Yan, B. Yang, X. Yang, et al. 2018. HMGB1 contributes to adriamycin-induced cardiotoxicity via up-regulating autophagy. Toxicol Lett 292: 115–122.CrossRef
27.
go back to reference Kim, J.E., W. Lee, S. Yang, S.H. Cho, M.C. Baek, G.Y. Song, et al. 2018. Suppressive effects of rare ginsenosides, Rk1 and Rg5, on HMGB1-mediated septic responses. Food Chem Toxicol 124: 45–53.CrossRef Kim, J.E., W. Lee, S. Yang, S.H. Cho, M.C. Baek, G.Y. Song, et al. 2018. Suppressive effects of rare ginsenosides, Rk1 and Rg5, on HMGB1-mediated septic responses. Food Chem Toxicol 124: 45–53.CrossRef
28.
go back to reference Dai, C., X. Xiao, D. Li, S. Tun, Y. Wang, T. Velkov, et al. 2018. Chloroquine ameliorates carbon tetrachloride-induced acute liver injury in mice via the concomitant inhibition of inflammation and induction of apoptosis. Cell Death Dis 9 (12): 1164.CrossRef Dai, C., X. Xiao, D. Li, S. Tun, Y. Wang, T. Velkov, et al. 2018. Chloroquine ameliorates carbon tetrachloride-induced acute liver injury in mice via the concomitant inhibition of inflammation and induction of apoptosis. Cell Death Dis 9 (12): 1164.CrossRef
29.
go back to reference Do, T., R. Tan, M. Bennett, M. Medvedovic, A.A. Grom, N. Shen, et al. 2018. MicroRNA networks associated with active systemic juvenile idiopathic arthritis regulate CD163 expression and anti-inflammatory functions in macrophages through two distinct mechanisms. J Leukoc Biol 103 (1): 71–85.CrossRef Do, T., R. Tan, M. Bennett, M. Medvedovic, A.A. Grom, N. Shen, et al. 2018. MicroRNA networks associated with active systemic juvenile idiopathic arthritis regulate CD163 expression and anti-inflammatory functions in macrophages through two distinct mechanisms. J Leukoc Biol 103 (1): 71–85.CrossRef
30.
go back to reference Ghorbani, S., F. Talebi, W.F. Chan, F. Masoumi, M. Vojgani, C. Power, et al. 2017. MicroRNA-181 variants regulate T cell phenotype in the context of autoimmune neuroinflammation. Front Immunol 8: 758.CrossRef Ghorbani, S., F. Talebi, W.F. Chan, F. Masoumi, M. Vojgani, C. Power, et al. 2017. MicroRNA-181 variants regulate T cell phenotype in the context of autoimmune neuroinflammation. Front Immunol 8: 758.CrossRef
Metadata
Title
MicroRNA-181b Inhibits Inflammatory Response and Reduces Myocardial Injury in Sepsis by Downregulating HMGB1
Authors
Lan Ling
Lida Zhi
Haifeng Wang
Yihuan Deng
Chengdong Gu
Publication date
01-08-2021
Publisher
Springer US
Published in
Inflammation / Issue 4/2021
Print ISSN: 0360-3997
Electronic ISSN: 1573-2576
DOI
https://doi.org/10.1007/s10753-020-01411-w

Other articles of this Issue 4/2021

Inflammation 4/2021 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine